Global COVID-19 Neutralizing Antibody Drugs Market Growth 2023-2029

February 2023 | 90 pages | ID: GDF687A7228CEN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

LPI (LP Information)' newest research report, the “COVID-19 Neutralizing Antibody Drugs Industry Forecast” looks at past sales and reviews total world COVID-19 Neutralizing Antibody Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected COVID-19 Neutralizing Antibody Drugs sales for 2023 through 2029. With COVID-19 Neutralizing Antibody Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world COVID-19 Neutralizing Antibody Drugs industry.

This Insight Report provides a comprehensive analysis of the global COVID-19 Neutralizing Antibody Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on COVID-19 Neutralizing Antibody Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global COVID-19 Neutralizing Antibody Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for COVID-19 Neutralizing Antibody Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global COVID-19 Neutralizing Antibody Drugs.

The global COVID-19 Neutralizing Antibody Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for COVID-19 Neutralizing Antibody Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for COVID-19 Neutralizing Antibody Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for COVID-19 Neutralizing Antibody Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key COVID-19 Neutralizing Antibody Drugs players cover Tychan, AstraZeneca, Molecular Partners AG/??, Eli Lilly, Regeneron Pharmaceuticals and Abpro, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of COVID-19 Neutralizing Antibody Drugs market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

• ACE2 Fusion Protein
• Neutralizing Antibody

Segmentation by application

• Hospital
• Clinic

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Tychan
• AstraZeneca
• Molecular Partners AG/??
• Eli Lilly
• Regeneron Pharmaceuticals
• Abpro

Key Questions Addressed in this Report

What is the 10-year outlook for the global COVID-19 Neutralizing Antibody Drugs market?

What factors are driving COVID-19 Neutralizing Antibody Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do COVID-19 Neutralizing Antibody Drugs market opportunities vary by end market size?

How does COVID-19 Neutralizing Antibody Drugs break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global COVID-19 Neutralizing Antibody Drugs Annual Sales 2018-2029
  2.1.2 World Current & Future Analysis for COVID-19 Neutralizing Antibody Drugs by Geographic Region, 2018, 2022 & 2029
  2.1.3 World Current & Future Analysis for COVID-19 Neutralizing Antibody Drugs by Country/Region, 2018, 2022 & 2029
2.2 COVID-19 Neutralizing Antibody Drugs Segment by Type
  2.2.1 ACE2 Fusion Protein
  2.2.2 Neutralizing Antibody
2.3 COVID-19 Neutralizing Antibody Drugs Sales by Type
  2.3.1 Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Type (2018-2023)
  2.3.2 Global COVID-19 Neutralizing Antibody Drugs Revenue and Market Share by Type (2018-2023)
  2.3.3 Global COVID-19 Neutralizing Antibody Drugs Sale Price by Type (2018-2023)
2.4 COVID-19 Neutralizing Antibody Drugs Segment by Application
  2.4.1 Hospital
  2.4.2 Clinic
2.5 COVID-19 Neutralizing Antibody Drugs Sales by Application
  2.5.1 Global COVID-19 Neutralizing Antibody Drugs Sale Market Share by Application (2018-2023)
  2.5.2 Global COVID-19 Neutralizing Antibody Drugs Revenue and Market Share by Application (2018-2023)
  2.5.3 Global COVID-19 Neutralizing Antibody Drugs Sale Price by Application (2018-2023)

3 GLOBAL COVID-19 NEUTRALIZING ANTIBODY DRUGS BY COMPANY

3.1 Global COVID-19 Neutralizing Antibody Drugs Breakdown Data by Company
  3.1.1 Global COVID-19 Neutralizing Antibody Drugs Annual Sales by Company (2018-2023)
  3.1.2 Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Company (2018-2023)
3.2 Global COVID-19 Neutralizing Antibody Drugs Annual Revenue by Company (2018-2023)
  3.2.1 Global COVID-19 Neutralizing Antibody Drugs Revenue by Company (2018-2023)
  3.2.2 Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Company (2018-2023)
3.3 Global COVID-19 Neutralizing Antibody Drugs Sale Price by Company
3.4 Key Manufacturers COVID-19 Neutralizing Antibody Drugs Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers COVID-19 Neutralizing Antibody Drugs Product Location Distribution
  3.4.2 Players COVID-19 Neutralizing Antibody Drugs Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR COVID-19 NEUTRALIZING ANTIBODY DRUGS BY GEOGRAPHIC REGION

4.1 World Historic COVID-19 Neutralizing Antibody Drugs Market Size by Geographic Region (2018-2023)
  4.1.1 Global COVID-19 Neutralizing Antibody Drugs Annual Sales by Geographic Region (2018-2023)
  4.1.2 Global COVID-19 Neutralizing Antibody Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic COVID-19 Neutralizing Antibody Drugs Market Size by Country/Region (2018-2023)
  4.2.1 Global COVID-19 Neutralizing Antibody Drugs Annual Sales by Country/Region (2018-2023)
  4.2.2 Global COVID-19 Neutralizing Antibody Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas COVID-19 Neutralizing Antibody Drugs Sales Growth
4.4 APAC COVID-19 Neutralizing Antibody Drugs Sales Growth
4.5 Europe COVID-19 Neutralizing Antibody Drugs Sales Growth
4.6 Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales Growth

5 AMERICAS

5.1 Americas COVID-19 Neutralizing Antibody Drugs Sales by Country
  5.1.1 Americas COVID-19 Neutralizing Antibody Drugs Sales by Country (2018-2023)
  5.1.2 Americas COVID-19 Neutralizing Antibody Drugs Revenue by Country (2018-2023)
5.2 Americas COVID-19 Neutralizing Antibody Drugs Sales by Type
5.3 Americas COVID-19 Neutralizing Antibody Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC COVID-19 Neutralizing Antibody Drugs Sales by Region
  6.1.1 APAC COVID-19 Neutralizing Antibody Drugs Sales by Region (2018-2023)
  6.1.2 APAC COVID-19 Neutralizing Antibody Drugs Revenue by Region (2018-2023)
6.2 APAC COVID-19 Neutralizing Antibody Drugs Sales by Type
6.3 APAC COVID-19 Neutralizing Antibody Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe COVID-19 Neutralizing Antibody Drugs by Country
  7.1.1 Europe COVID-19 Neutralizing Antibody Drugs Sales by Country (2018-2023)
  7.1.2 Europe COVID-19 Neutralizing Antibody Drugs Revenue by Country (2018-2023)
7.2 Europe COVID-19 Neutralizing Antibody Drugs Sales by Type
7.3 Europe COVID-19 Neutralizing Antibody Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa COVID-19 Neutralizing Antibody Drugs by Country
  8.1.1 Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales by Country (2018-2023)
  8.1.2 Middle East & Africa COVID-19 Neutralizing Antibody Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales by Type
8.3 Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of COVID-19 Neutralizing Antibody Drugs
10.3 Manufacturing Process Analysis of COVID-19 Neutralizing Antibody Drugs
10.4 Industry Chain Structure of COVID-19 Neutralizing Antibody Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 COVID-19 Neutralizing Antibody Drugs Distributors
11.3 COVID-19 Neutralizing Antibody Drugs Customer

12 WORLD FORECAST REVIEW FOR COVID-19 NEUTRALIZING ANTIBODY DRUGS BY GEOGRAPHIC REGION

12.1 Global COVID-19 Neutralizing Antibody Drugs Market Size Forecast by Region
  12.1.1 Global COVID-19 Neutralizing Antibody Drugs Forecast by Region (2024-2029)
  12.1.2 Global COVID-19 Neutralizing Antibody Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global COVID-19 Neutralizing Antibody Drugs Forecast by Type
12.7 Global COVID-19 Neutralizing Antibody Drugs Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Tychan
  13.1.1 Tychan Company Information
  13.1.2 Tychan COVID-19 Neutralizing Antibody Drugs Product Portfolios and Specifications
  13.1.3 Tychan COVID-19 Neutralizing Antibody Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
  13.1.4 Tychan Main Business Overview
  13.1.5 Tychan Latest Developments
13.2 AstraZeneca
  13.2.1 AstraZeneca Company Information
  13.2.2 AstraZeneca COVID-19 Neutralizing Antibody Drugs Product Portfolios and Specifications
  13.2.3 AstraZeneca COVID-19 Neutralizing Antibody Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
  13.2.4 AstraZeneca Main Business Overview
  13.2.5 AstraZeneca Latest Developments
13.3 Molecular Partners AG/??
  13.3.1 Molecular Partners AG/?? Company Information
  13.3.2 Molecular Partners AG/?? COVID-19 Neutralizing Antibody Drugs Product Portfolios and Specifications
  13.3.3 Molecular Partners AG/?? COVID-19 Neutralizing Antibody Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
  13.3.4 Molecular Partners AG/?? Main Business Overview
  13.3.5 Molecular Partners AG/?? Latest Developments
13.4 Eli Lilly
  13.4.1 Eli Lilly Company Information
  13.4.2 Eli Lilly COVID-19 Neutralizing Antibody Drugs Product Portfolios and Specifications
  13.4.3 Eli Lilly COVID-19 Neutralizing Antibody Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
  13.4.4 Eli Lilly Main Business Overview
  13.4.5 Eli Lilly Latest Developments
13.5 Regeneron Pharmaceuticals
  13.5.1 Regeneron Pharmaceuticals Company Information
  13.5.2 Regeneron Pharmaceuticals COVID-19 Neutralizing Antibody Drugs Product Portfolios and Specifications
  13.5.3 Regeneron Pharmaceuticals COVID-19 Neutralizing Antibody Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
  13.5.4 Regeneron Pharmaceuticals Main Business Overview
  13.5.5 Regeneron Pharmaceuticals Latest Developments
13.6 Abpro
  13.6.1 Abpro Company Information
  13.6.2 Abpro COVID-19 Neutralizing Antibody Drugs Product Portfolios and Specifications
  13.6.3 Abpro COVID-19 Neutralizing Antibody Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
  13.6.4 Abpro Main Business Overview
  13.6.5 Abpro Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. COVID-19 Neutralizing Antibody Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. COVID-19 Neutralizing Antibody Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of ACE2 Fusion Protein
Table 4. Major Players of Neutralizing Antibody
Table 5. Global COVID-19 Neutralizing Antibody Drugs Sales by Type (2018-2023) & (K Units)
Table 6. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Type (2018-2023)
Table 7. Global COVID-19 Neutralizing Antibody Drugs Revenue by Type (2018-2023) & ($ million)
Table 8. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Type (2018-2023)
Table 9. Global COVID-19 Neutralizing Antibody Drugs Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global COVID-19 Neutralizing Antibody Drugs Sales by Application (2018-2023) & (K Units)
Table 11. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Application (2018-2023)
Table 12. Global COVID-19 Neutralizing Antibody Drugs Revenue by Application (2018-2023)
Table 13. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Application (2018-2023)
Table 14. Global COVID-19 Neutralizing Antibody Drugs Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global COVID-19 Neutralizing Antibody Drugs Sales by Company (2018-2023) & (K Units)
Table 16. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Company (2018-2023)
Table 17. Global COVID-19 Neutralizing Antibody Drugs Revenue by Company (2018-2023) ($ Millions)
Table 18. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Company (2018-2023)
Table 19. Global COVID-19 Neutralizing Antibody Drugs Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers COVID-19 Neutralizing Antibody Drugs Producing Area Distribution and Sales Area
Table 21. Players COVID-19 Neutralizing Antibody Drugs Products Offered
Table 22. COVID-19 Neutralizing Antibody Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global COVID-19 Neutralizing Antibody Drugs Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share Geographic Region (2018-2023)
Table 27. Global COVID-19 Neutralizing Antibody Drugs Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global COVID-19 Neutralizing Antibody Drugs Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Country/Region (2018-2023)
Table 31. Global COVID-19 Neutralizing Antibody Drugs Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas COVID-19 Neutralizing Antibody Drugs Sales by Country (2018-2023) & (K Units)
Table 34. Americas COVID-19 Neutralizing Antibody Drugs Sales Market Share by Country (2018-2023)
Table 35. Americas COVID-19 Neutralizing Antibody Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Country (2018-2023)
Table 37. Americas COVID-19 Neutralizing Antibody Drugs Sales by Type (2018-2023) & (K Units)
Table 38. Americas COVID-19 Neutralizing Antibody Drugs Sales by Application (2018-2023) & (K Units)
Table 39. APAC COVID-19 Neutralizing Antibody Drugs Sales by Region (2018-2023) & (K Units)
Table 40. APAC COVID-19 Neutralizing Antibody Drugs Sales Market Share by Region (2018-2023)
Table 41. APAC COVID-19 Neutralizing Antibody Drugs Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Region (2018-2023)
Table 43. APAC COVID-19 Neutralizing Antibody Drugs Sales by Type (2018-2023) & (K Units)
Table 44. APAC COVID-19 Neutralizing Antibody Drugs Sales by Application (2018-2023) & (K Units)
Table 45. Europe COVID-19 Neutralizing Antibody Drugs Sales by Country (2018-2023) & (K Units)
Table 46. Europe COVID-19 Neutralizing Antibody Drugs Sales Market Share by Country (2018-2023)
Table 47. Europe COVID-19 Neutralizing Antibody Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Country (2018-2023)
Table 49. Europe COVID-19 Neutralizing Antibody Drugs Sales by Type (2018-2023) & (K Units)
Table 50. Europe COVID-19 Neutralizing Antibody Drugs Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of COVID-19 Neutralizing Antibody Drugs
Table 58. Key Market Challenges & Risks of COVID-19 Neutralizing Antibody Drugs
Table 59. Key Industry Trends of COVID-19 Neutralizing Antibody Drugs
Table 60. COVID-19 Neutralizing Antibody Drugs Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. COVID-19 Neutralizing Antibody Drugs Distributors List
Table 63. COVID-19 Neutralizing Antibody Drugs Customer List
Table 64. Global COVID-19 Neutralizing Antibody Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global COVID-19 Neutralizing Antibody Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas COVID-19 Neutralizing Antibody Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas COVID-19 Neutralizing Antibody Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC COVID-19 Neutralizing Antibody Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC COVID-19 Neutralizing Antibody Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe COVID-19 Neutralizing Antibody Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe COVID-19 Neutralizing Antibody Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global COVID-19 Neutralizing Antibody Drugs Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global COVID-19 Neutralizing Antibody Drugs Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global COVID-19 Neutralizing Antibody Drugs Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global COVID-19 Neutralizing Antibody Drugs Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Tychan Basic Information, COVID-19 Neutralizing Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 79. Tychan COVID-19 Neutralizing Antibody Drugs Product Portfolios and Specifications
Table 80. Tychan COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Tychan Main Business
Table 82. Tychan Latest Developments
Table 83. AstraZeneca Basic Information, COVID-19 Neutralizing Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. AstraZeneca COVID-19 Neutralizing Antibody Drugs Product Portfolios and Specifications
Table 85. AstraZeneca COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. AstraZeneca Main Business
Table 87. AstraZeneca Latest Developments
Table 88. Molecular Partners AG/?? Basic Information, COVID-19 Neutralizing Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. Molecular Partners AG/?? COVID-19 Neutralizing Antibody Drugs Product Portfolios and Specifications
Table 90. Molecular Partners AG/?? COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Molecular Partners AG/?? Main Business
Table 92. Molecular Partners AG/?? Latest Developments
Table 93. Eli Lilly Basic Information, COVID-19 Neutralizing Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. Eli Lilly COVID-19 Neutralizing Antibody Drugs Product Portfolios and Specifications
Table 95. Eli Lilly COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. Eli Lilly Main Business
Table 97. Eli Lilly Latest Developments
Table 98. Regeneron Pharmaceuticals Basic Information, COVID-19 Neutralizing Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. Regeneron Pharmaceuticals COVID-19 Neutralizing Antibody Drugs Product Portfolios and Specifications
Table 100. Regeneron Pharmaceuticals COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. Regeneron Pharmaceuticals Main Business
Table 102. Regeneron Pharmaceuticals Latest Developments
Table 103. Abpro Basic Information, COVID-19 Neutralizing Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. Abpro COVID-19 Neutralizing Antibody Drugs Product Portfolios and Specifications
Table 105. Abpro COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. Abpro Main Business
Table 107. Abpro Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of COVID-19 Neutralizing Antibody Drugs
Figure 2. COVID-19 Neutralizing Antibody Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global COVID-19 Neutralizing Antibody Drugs Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global COVID-19 Neutralizing Antibody Drugs Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. COVID-19 Neutralizing Antibody Drugs Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of ACE2 Fusion Protein
Figure 10. Product Picture of Neutralizing Antibody
Figure 11. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Type in 2022
Figure 12. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Type (2018-2023)
Figure 13. COVID-19 Neutralizing Antibody Drugs Consumed in Hospital
Figure 14. Global COVID-19 Neutralizing Antibody Drugs Market: Hospital (2018-2023) & (K Units)
Figure 15. COVID-19 Neutralizing Antibody Drugs Consumed in Clinic
Figure 16. Global COVID-19 Neutralizing Antibody Drugs Market: Clinic (2018-2023) & (K Units)
Figure 17. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Application (2022)
Figure 18. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Application in 2022
Figure 19. COVID-19 Neutralizing Antibody Drugs Sales Market by Company in 2022 (K Units)
Figure 20. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Company in 2022
Figure 21. COVID-19 Neutralizing Antibody Drugs Revenue Market by Company in 2022 ($ Million)
Figure 22. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Company in 2022
Figure 23. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Geographic Region (2018-2023)
Figure 24. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Geographic Region in 2022
Figure 25. Americas COVID-19 Neutralizing Antibody Drugs Sales 2018-2023 (K Units)
Figure 26. Americas COVID-19 Neutralizing Antibody Drugs Revenue 2018-2023 ($ Millions)
Figure 27. APAC COVID-19 Neutralizing Antibody Drugs Sales 2018-2023 (K Units)
Figure 28. APAC COVID-19 Neutralizing Antibody Drugs Revenue 2018-2023 ($ Millions)
Figure 29. Europe COVID-19 Neutralizing Antibody Drugs Sales 2018-2023 (K Units)
Figure 30. Europe COVID-19 Neutralizing Antibody Drugs Revenue 2018-2023 ($ Millions)
Figure 31. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales 2018-2023 (K Units)
Figure 32. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Revenue 2018-2023 ($ Millions)
Figure 33. Americas COVID-19 Neutralizing Antibody Drugs Sales Market Share by Country in 2022
Figure 34. Americas COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Country in 2022
Figure 35. Americas COVID-19 Neutralizing Antibody Drugs Sales Market Share by Type (2018-2023)
Figure 36. Americas COVID-19 Neutralizing Antibody Drugs Sales Market Share by Application (2018-2023)
Figure 37. United States COVID-19 Neutralizing Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 38. Canada COVID-19 Neutralizing Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 39. Mexico COVID-19 Neutralizing Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 40. Brazil COVID-19 Neutralizing Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 41. APAC COVID-19 Neutralizing Antibody Drugs Sales Market Share by Region in 2022
Figure 42. APAC COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Regions in 2022
Figure 43. APAC COVID-19 Neutralizing Antibody Drugs Sales Market Share by Type (2018-2023)
Figure 44. APAC COVID-19 Neutralizing Antibody Drugs Sales Market Share by Application (2018-2023)
Figure 45. China COVID-19 Neutralizing Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 46. Japan COVID-19 Neutralizing Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 47. South Korea COVID-19 Neutralizing Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 48. Southeast Asia COVID-19 Neutralizing Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 49. India COVID-19 Neutralizing Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 50. Australia COVID-19 Neutralizing Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 51. China Taiwan COVID-19 Neutralizing Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 52. Europe COVID-19 Neutralizing Antibody Drugs Sales Market Share by Country in 2022
Figure 53. Europe COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Country in 2022
Figure 54. Europe COVID-19 Neutralizing Antibody Drugs Sales Market Share by Type (2018-2023)
Figure 55. Europe COVID-19 Neutralizing Antibody Drugs Sales Market Share by Application (2018-2023)
Figure 56. Germany COVID-19 Neutralizing Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 57. France COVID-19 Neutralizing Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 58. UK COVID-19 Neutralizing Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 59. Italy COVID-19 Neutralizing Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 60. Russia COVID-19 Neutralizing Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 61. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales Market Share by Country in 2022
Figure 62. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Country in 2022
Figure 63. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales Market Share by Type (2018-2023)
Figure 64. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales Market Share by Application (2018-2023)
Figure 65. Egypt COVID-19 Neutralizing Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 66. South Africa COVID-19 Neutralizing Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 67. Israel COVID-19 Neutralizing Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 68. Turkey COVID-19 Neutralizing Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 69. GCC Country COVID-19 Neutralizing Antibody Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 70. Manufacturing Cost Structure Analysis of COVID-19 Neutralizing Antibody Drugs in 2022
Figure 71. Manufacturing Process Analysis of COVID-19 Neutralizing Antibody Drugs
Figure 72. Industry Chain Structure of COVID-19 Neutralizing Antibody Drugs
Figure 73. Channels of Distribution
Figure 74. Global COVID-19 Neutralizing Antibody Drugs Sales Market Forecast by Region (2024-2029)
Figure 75. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share Forecast by Region (2024-2029)
Figure 76. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share Forecast by Type (2024-2029)
Figure 77. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share Forecast by Type (2024-2029)
Figure 78. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share Forecast by Application (2024-2029)
Figure 79. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share Forecast by Application (2024-2029)